HCC
BHC icon

Hirtle Callaghan & Co’s Bausch Health BHC Stock Holding History

Hirtle Callaghan & Co’s Portfolio BHC Stock Details BHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,039
Closed -$292K – 53
2014
Q4 		$292K Hold
2,039
– – 0.07% 160
2014
Q3 		$268K Sell
2,039
-600
-23% -$71.5K 0.04% 163
2014
Q2 		$333K Buy
2,639
+600
+29% +$76.5K 0.05% 187
2014
Q1 		$269K Hold
2,039
– – 0.04% 198
2013
Q4 		$239K Buy
2,039
+426
+26% +$46.7K 0.03% 210
2013
Q3 		$168K Buy
+1,613
New +$157K 0.03% 236

Other funds holding BHC

RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PSCM
Pershing Square Capital Management New York $13.7B AUM 13.45% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.04B AUM 1.15% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Hirtle Callaghan & Co's BHC Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Bausch Health (BHC) in Q1 2015, closing a stake of 2,039 shares — an estimated $292K sold.

Hirtle Callaghan & Co first reported a position in BHC in Q3 2013 and held it in 6 quarters. The position peaked at $333K in Q2 2014. 556 funds tracked by Wall St. Rank hold BHC as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining Bausch Health position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 2,039 Bausch Health shares in Q1 2015, an estimated $292K.
  • Hirtle Callaghan & Co first reported a position in Bausch Health in Q3 2013 and held it in 6 quarters.
  • Hirtle Callaghan & Co's Bausch Health position peaked at $333K in Q2 2014.
  • 556 funds tracked by Wall St. Rank held Bausch Health as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.